Topology Analysis of Drug Binding Sites on Serum Proteins using Photoaffinity Labeling Techniques
Topology Analysis of Drug Binding Sites on Serum Proteins using Photoaffinity Labeling Techniques
批准号:
09470505
负责人:
OTAGIRI Masaki
金额:
$7.17万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Arylpropionic acid NSAIDs and benzodiazepines are known to bind to site II of human serum albumin (HAS). However, information on the amino acids of the binding site that interact with these drugs is still insufficient. Ketoprofen (KP), an arylpropionic acid NSAID possessing benzophenone moiety and flunitrazepam (FNZP), a benzodiazepine with nitrophenyl moiety were used as photoaffinity labeling agents to define the microenvironment of site II on HAS. CNBr fragments of the [ィイD114ィエD1C]KP photolabeled HAS of about 14 kDa and 9 kDa incorporated radioactivity. Competition experiment showed that the 14 kDa band was the specifically photolabeled band. The 14 kDa peptide was redigested with Achromobacter lyticus protease I (AP I) and then separated with capillary HPLC. The amino acid sequence of the [ィイD114ィエD1C]KP photolabeled peptide was concluded to be XCTESLVNRR, which corresponded to 476C - 500K of HAS. This region of HAS was reported to be part of the site II hydrophobic binding pocket. Benzodiazepine (BDZ) drugs are known to bind to both human serum albumin (HAS) and alphal-acid glycoprotein (AGP). It is generally accepted that benzodiazepine drugs bind to subdomain III A (site II) of HAS. CNBr fragment of about 20 kDa of the [ィイD13ィエD1H]FNZP photolabeled HAS incorporated most of the radioactivity while the major photolabeled band of AGP seemed to be the N-terminus CNBr fragment The 20 kDa band radioactivity decreased sharply when HAS was photolabeled with FNZP in the presence of myristic acid but not in the presence of diazepam. The reverse displacement effect was observed for the N-terminus band of AGP. Further fluorescent probe displacement experiment showed that FNZP failed to displace the site II probe dansylsarcosine. The key position in the BDZ molecular structure that governs the binding affinity to site II of HAS was concluded to be position 7 of ring A.
期刊论文(36)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kosa T, et al.: "Species differences of serum albumins: II. Chemical and thermal stability"Pharm Res.. 15(3). 449-454 (1998)
Kosa T 等人:“血清白蛋白的物种差异:II. 化学和热稳定性”Pharm Res.. 15(3)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Sakai T, et al.: "Stereoselective serum protein binding of ketoprofen in liver diseases"Enantiomer. 4(5). 477-482 (1999)
Sakai T 等人:“肝脏疾病中酮洛芬的立体选择性血清蛋白结合”对映体。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Sakai et al: "Stereoselective serum protein binding of ketoprofen in liver diseases"Enantiomer. 4・(5). 477-482 (1999)
T.Sakai 等人:“肝脏疾病中酮洛芬的立体选择性血清蛋白结合”4·(5)477-482 (1999)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Komori: "Effect of clarithromycin on α_1-acid glycoprotein levels in normal and diabetic rats" Research Communication in Molecular Pathology and Pharmacology. 101(3). 233-240 (1998)
T. Komori:“克拉霉素对正常和糖尿病大鼠 α_1-酸性糖蛋白水平的影响”《分子病理学和药理学研究通讯》101(3) (1998)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M.Sakai: "Effects of absorption enhancers on cytoskeletal actin filaments in Caco-2 cell monolayers" Life Sciences. 63(1). 45-54 (1998)
M.Sakai:“吸收增强剂对 Caco-2 单层细胞骨架肌动蛋白丝的影响”生命科学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 35 条
Development of novel hybrid anti-oxidant based on albumin fusion technology and its therapeutic application on acute radiation syndrome
-
批准号:15K15008
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2015
-
负责人:OTAGIRI Masaki
-
依托单位:
Construction of an Innovative Bone Marrow Delivery System of Anticancer Drug for Control of Malignant Tumors' Bone Metastasis
-
批准号:25670085
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2013
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Evaluation of Next Generation Albumin-thioredoxin Fusion Protein for Multiple Organ Failure Treatment
-
批准号:24390043
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.06万
-
财政年份:2012
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of effective blood purification treatment method usingHSA bound toxic comnpodus designed bpyhase display tecnohlogy
-
批准号:23659088
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of Redox Controlling Nanomedicine Based on Albumin Fusion
-
批准号:21390177
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.23万
-
财政年份:2009
-
负责人:OTAGIRI Masaki
-
依托单位:
Application of functional recombinant HSAs as a DDS carrier
-
批准号:18390051
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.09万
-
财政年份:2006
-
负责人:OTAGIRI Masaki
-
依托单位:
The development of next-generation albumin preparation by mutagenesi s studies
-
批准号:14370759
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.58万
-
财政年份:2002
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Evaluation of Albumin Mutants for Clinical Application
-
批准号:11694298
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$4.67万
-
财政年份:1999
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Functional Evaluation of Albumin Mutants for Improving Medicinal Efficacy
-
批准号:10557245
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$6.85万
-
财政年份:1998
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of Pharmaceutical Additives-Evaluation of Protein and Polysaccharide Hydrolysates as Carrier to Enhance Absorption Rate of Drug
-
批准号:07557146
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$2.37万
-
财政年份:1995
-
负责人:OTAGIRI Masaki
-
依托单位:
Microenviromental Analysis of Drug Binding Site on Albumin by Point-mutation and Using Probe
-
批准号:06672146
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.54万
-
财政年份:1994
-
负责人:OTAGIRI Masaki
-
依托单位:
Microenvironmental Analysis of Drug Binding Sites on Human Serum Albumin and alpha_1-Acid Glycoprotein
-
批准号:02807196
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.02万
-
财政年份:1990
-
负责人:OTAGIRI Masaki
-
依托单位:
海外基金